Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Share Options
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it has granted options over a total of 431,354 new ordinary shares of £0.01 each in the Company ("Options") (representing 0.45 per cent. of the Company's issued share capital) to certain employees of the Company, including the Directors and PDMR named below.
| Name | Position | Deferred Bonus Options issued Under 2020 LTIP Scheme* | Total Options held post issue | Options held as a percentage of issued share capital | Ordinary Shares held | Ordinary Shares held as a percentage of issued share capital
|
| Neil Clark | Chief Executive Officer | 52,264 | 1,424,798 | 1.50% | 117,033 | 0.12% |
| Shaun Claydon | Chief Financial Officer | 47,100 | 911,001 | 0.96% | 24,286 | 0.03% |
| William Love** | Chief Scientific Officer | 43,313 | 959,549 | 1.01% | 6,509,500 | 6.83% |
| Yuri Martina | Chief Medical Officer | 71,177 | 261,177 | 0.27% | - | - |
* granted in respect of bonuses due for the financial year ended 31 December 2022
**3,317,700 of these Ordinary Shares are held by William Love and 3,191,800 are held by Carol Love
The above options granted to the Directors and PDMR represent awards granted under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options (the "Employee LTIP 2020"). The above options granted to the Directors and PDMR have been granted with a nominal exercise price, will vest on 1 February 2025 and are exercisable up to 10 years from the date of grant. Including the grant of these Options, the Company will have outstanding options over approximately 8.72 per cent. of its issued share capital.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the Company, please visit https://www.destinypharma.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Neil Clark |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 52,264 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 12 May 2023 |
| f) | Place of the transaction | Outside of trading venue |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Shaun Claydon |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 47,100 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 12 May 2023 |
| f) | Place of the transaction | Outside of trading venue |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | William Love |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Scientific Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 43,313 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 12 May 2023 |
| f) | Place of the transaction | Outside of trading venue |
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Yuri Martina |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Medical Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Destiny Pharma plc |
| b) | LEI | 213800O9WH9Z38EHAC95 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") the 2020 Destiny Pharma plc Long Term Incentive Plan.
|
| Identification code | DEST GB00BDHSP575 | |
| b) | Nature of the transaction | Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan. |
| c) | Price(s) and volume(s) | 1 pence exercise price per Ordinary Share 71,177 Ordinary Shares |
| d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
| e) | Date of the transaction | 12 May 2023 |
| f) | Place of the transaction | Outside of trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.